Bladder Cancer: Diagnosis and Treatment

 

Am Fam Physician. 2017 Oct 15;96(8):507-514.

  Patient information: See related handout on bladder cancer.

Author disclosure: No relevant financial affiliations.

Bladder cancer is the sixth most prevalent malignancy in the United States and causes more than 16,000 deaths annually. The most common clinical presentation is asymptomatic hematuria, which should prompt evaluation with cystoscopy, renal function testing, and upper urinary tract imaging in adults 35 years and older and in those with irritative voiding symptoms, risk factors for bladder cancer, or gross hematuria at any age. Transurethral resection of the bladder tumor allows for definitive diagnosis, staging, and primary treatment. Non–muscle-invasive disease is treated with transurethral resection, most often followed by intravesical bacille Calmette-Guérin or intravesical chemotherapy. Bladder cancer that invades the muscle layer is typically treated with radical cystectomy and neoadjuvant chemotherapy because of higher rates of progression and recurrence. No major organization recommends screening asymptomatic adults for bladder cancer, and the U.S. Preventive Services Task Force concluded that current evidence is insufficient to assess the balance of benefits and harms of screening.

Bladder cancer comprises 5% of new cancer diagnoses in the United States and is the sixth most prevalent malignancy.1 About 90% of affected patients are older than 55 years, with a mean age at diagnosis of 73 years.1 Men are three to four times more likely than women to develop the disease, with a lifetime risk of one in 26 for men and one in 88 for women.1 Bladder cancer affects whites about two times more often than blacks or Hispanics, but it is more likely to be diagnosed at an advanced stage in black patients.1 As the incidence of the disease has decreased, bladder cancer–related mortality has decreased for women but remains unchanged for men.1 An estimated 16,400 deaths were caused by bladder cancer in 2016.1

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferencesComments

Urine cytology and testing for urine tumor markers should not be performed routinely for evaluation of bladder cancer.

C

21, 29

Urine cytology has > 90% sensitivity for detection of high-grade tumors and carcinoma in situ; it can be of benefit in patients with high pretest probability of disease.

Cystoscopy should be performed in all patients with gross hematuria, all patients 35 years and older who have microscopic hematuria, and all patients with symptomatic microscopic hematuria of unclear etiology, regardless of age.

C

21

Initial evaluation for bladder cancer should include imaging of the upper urinary tract.

C

27, 30

Computed tomography urography is preferred.

Non–muscle-invasive bladder cancer should be treated with transurethral resection of the tumor, with or without intravesical instillation of immunotherapy or chemotherapy.

C

20, 27, 32

Cisplatin-based neoadjuvant chemotherapy should be considered in addition to radical cystectomy with extended lymphadenectomy for additional survival benefit in patients with muscle-invasive bladder cancer.

A

29

There is an absolute five-year survival benefit of 5% to 8%.

The U.S. Preventive Services Task Force concludes the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.

C

33

The American Academy of Family Physicians concurs.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferencesComments

Urine cytology and testing for urine tumor markers should not be performed routinely for evaluation of bladder cancer.

C

21, 29

Urine cytology has > 90% sensitivity for detection of high-grade tumors and carcinoma in situ; it can be of benefit in patients with high pretest probability of disease.

Cystoscopy should be performed in all patients with gross hematuria, all patients 35 years and older who have microscopic hematuria, and all patients with symptomatic microscopic hematuria of unclear etiology, regardless of age.

C

21

Initial evaluation for bladder cancer should include imaging of the upper urinary tract.

C

27, 30

Computed tomography urography is preferred.

Non–muscle-invasive bladder cancer should be treated with transurethral resection of the tumor, with or without intravesical instillation of immunotherapy or chemotherapy.

C

20, 27, 32

Cisplatin-based neoadjuvant chemotherapy should be considered in addition to radical cystectomy with extended lymphadenectomy for additional survival benefit in patients with muscle-invasive bladder cancer.

A

29

There is an absolute five-year survival benefit of 5% to 8%.

The U.S. Preventive Services Task Force concludes the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.

C

33

The American Academy of Family Physicians concurs.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

 Enlarge     Print

BEST PRACTICES IN UROLOGY: RECOMMENDATIONS FROM THE CHOOSING WISELY CAMPAIGN

RecommendationSponsoring organization

Do not diagnose microhematuria solely on the results of urine dipstick testing (macroscopic analysis).

American Urological Association


Source: For more information on the Choosing Wisely Campaign, see http://www.choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/afp/recommendations/search.htm.

BEST PRACTICES IN UROLOGY: RECOMMENDATIONS FROM THE CHOOSING WISELY CAMPAIGN

RecommendationSponsoring organization

Do not diagnose microhematuria solely on the results of urine dipstick testing (macroscopic analysis).

American Urological Association


Source: For more information on the Choosing Wisely Campaign, see http://www.choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/afp/recommendations/search.htm.

Risk Factors

Established risk factors for bladder cancer include male sex, older age, white race, occupational exposure to certain chemicals, pelvic radiation, use of medications such as cyclophosphamide, chronic bladder infection/irritation, personal or family history of bladder cancer, and cigarette smoking2  (Table 1216). Studies have also suggested additional associations including diabetes mellitus, obesity, and human papillomavirus.8,14,15 Use of pioglitazone (Actos) for more than one year is independently associated with a slightly increased risk of bladder cancer.13 Consuming large amounts of processed red meat may also slightly increase risk.4

 Enlarge     Print

Table 1.

Established and Likely Risk Factors for Bladder Cancer

Behavioral

Cigarette smoking2,3

Consumption of processed red meat*4

Chemical exposure

Arsenic-contaminated water2

Chronic infection/irritation

Chronic kidney and bladder stones5

Chronic urinary tract infections2

Indwelling catheter (long-term)2,6

Schistosomiasis2,7

Genetics

Personal or family history of bladder cancer, especially at an early age2,8

Iatrogenic

Aristolochia herbal preparations2

Computed tomography in childhood or adolescence9

Cyclophosphamide2,10,11

Pelvic radiation therapy2,6,11

Phenacetin (no longer available in the United States)12

Pioglitazone (Actos) use for more than one year*13

Medical conditions

Diabetes mellitus*14

Human papillomavirus infection*15

Obesity*8

Renal transplant recipient*10

Occupational exposures

Exposure to aromatic amines (beta-naphthylamine) used in the manufacturing of chemical dyes and pharmaceuticals, and in gas treatment plants 2,3,7,8

Farming in Africa and the Middle East (increased risk of schistosomiasis)7

Manufacturing (cable, paint, petroleum, tire and rubber, textile); service industry (hairdressers, painters, truck drivers)3,7,16


*—Likely risk factors.

Information from references 2 through 16.

Table 1.

Established and Likely Risk Factors for Bladder Cancer

Behavioral

Cigarette smoking2,3

Consumption of processed red meat*4

Chemical exposure

Arsenic-contaminated water2

Chronic infection/irritation

Chronic kidney and bladder stones5

Chronic urinary tract infections2

Indwelling catheter (long-term)2,6

Schistosomiasis2,7

Genetics

Personal or family history of bladder cancer, especially at an early age2,8

Iatrogenic

Aristolochia herbal preparations2

Computed tomography in childhood or adolescence9

Cyclophosphamide2,10,11

Pelvic radiation therapy2,6,11

Phenacetin (no longer available in the United States)12

Pioglitazone (Actos) use for more than one year*13

Medical conditions

Diabetes mellitus*14

Human papillomavirus infection*15

Obesity*8

Renal transplant recipient*10

Occupational exposures

Exposure to aromatic amines (beta-naphthylamine) used in the manufacturing of chemical dyes and pharmaceuticals, and in gas treatment plants 2,3,7,8

Farming in Africa and the Middle East (increased risk of schistosomiasis)7

Manufacturing (cable, paint, petroleum, tire and rubber, textile); service industry (hairdressers, painters, truck drivers)3,7,16


*—Likely risk factors.

Information from references 2 through 16.

Pathology

Urothelial (transitional cell) carcinoma is the most common type of bladder cancer, accounting for approximately 90% of cases 17  (eTable A). Nonurothelial bladder cancers include squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and mixed histology tumors, with squamous cell and adenocarcinomas making up the majority of nonurothelial tumors.18 Although squamous cell carcinoma represents only a small fraction of bladder cancer cases in the developed world, it is the most common type in places where schistosomiasis is endemic, accounting for up to 81% of cases in these areas.19

 Enlarge     Print

eTable A.

World Health Organization/International Society of Urological Pathology Classification of Bladder Cancer

Epithelial neoplasms (99%)

Urothelial (transitional cell) (90%)

Invasive urothelial carcinoma: lamina propria or muscularis propria invasion

Papillary urothelial carcinoma: low malignant potential, low-grade, or high-grade

Papilloma: flat or papillary

Nonurothelial (9%)

Adenocarcinoma

Rare neoplasms

Small cell carcinoma

Squamous cell carcinoma

Nonepithelial (mesenchymal) neoplasms (1%)

Benign

Hemangioma

Leiomyoma

Lipoma

Neurofibroma

Paraganglioma

Malignant

Angiosarcoma

Leiomyosarcoma

Malignant fibrous histiocytoma

Osteosarcoma

Rhabdomyosarcoma


Information from:

Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol . 1998;22(12):1435–1448.

Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol. 2009;22(suppl 2):S60–S69.

eTable A.

World Health Organization/International Society of Urological Pathology Classification of Bladder Cancer

Epithelial neoplasms (99%)

Urothelial (transitional cell) (90%)

Invasive urothelial carcinoma: lamina propria or muscularis propria invasion

Papillary urothelial carcinoma: low malignant potential, low-grade, or high-grade

Papilloma: flat or papillary

Nonurothelial (9%)

Adenocarcinoma

Rare neoplasms

Small cell carcinoma

Squamous cell carcinoma

Nonepithelial (mesenchymal) neoplasms (1%)

Benign

Hemangioma

Leiomyoma

Lipoma

Neurofibroma

Paraganglioma

Malignant

Angiosarcoma

Leiomyosarcoma

Malignant fibrous histiocytoma

Osteosarcoma

Rhabdomyosarcoma


Information from:

Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol . 1998;22(12):1435–1448.

Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol. 2009;22(suppl 2):S60–S69.

Clinical Presentation

Painless hematuria is the most common presenting sign of bladder cancer 20,21  (Table 2 22). Approximately 1.3% of patients with asymptomatic microscopic hematuria (three or more red blood cells per high-power field in a properly collected specimen in the absence of an obvious benign cause 20,21) will have bladder cancer, with estimates ranging from 0.4% to 6.5%.20 Gross hematuria is associated with a higher rate of malignancy (estimated at 20%).23,24 Irritative voiding symptoms are often present (e.g., urinary frequency, urgency, nocturia, dysuria).20 Obstructive symptoms, such as reduced or intermittent urine stream, straining, or feeling of incomplete voiding, may be present if the tumor is near the bladder neck or urethra.20

 Enlarge     Print

Table 2.

Signs and Symptoms of Bladder Cancer

Hematuria (gross or microscopic)

Irritative symptoms (e.g., dysuria, frequency, nocturia, urge incontinence, urgency)

Obstructive symptoms (e.g., decreased force of stream, feeling of incomplete voiding, intermittent stream, straining)

Signs and symptoms of metastases or advanced disease (e.g., abdominal, bone, flank, or pelvic pain; anorexia, cachexia, or pallor; lower-extremity edema; renal failure; respiratory symptoms; suprapubic palpable mass)


Information from reference 22.

Table 2.

Signs and Symptoms of Bladder Cancer

Hematuria (gross or microscopic)

Irritative symptoms (e.g., dysuria, frequency, nocturia, urge incontinence, urgency)

Obstructive symptoms (e.g., decreased force of stream, feeling of incomplete voiding, intermittent stream, straining)

Signs and symptoms of metastases or advanced disease (e.g., abdominal, bone, flank, or pelvic pain; anorexia, cachexia, or pallor; lower-extremity edema; renal failure; respiratory symptoms; suprapubic palpable mass)


Information from reference 22.

Patients with advanced disease may present with symptoms related to metastatic involvement.22,25 The most common sites for metastasis include the lymph nodes, bone, lung, liver, and peritoneum.26 Physical examination findings are often unremarkable in patients with bladder cancer unless there is advanced or metastatic disease, which may demonstrate a palpable renal or bladder mass.20

Diagnosis

The initial evaluation of a patient with suspected bladder cancer relies on cystoscopy, assessment of renal function, and imaging of the upper urinary tract, preferably with computed tomography (CT) urography.21,27 The suggested workup for microscopic hematuria is shown in Figure 1.28

 Enlarge     Print

Diagnosis and Management of Incidentally Discovered Microscopic Hematuria

Figure 1.

Algorithm for the diagnosis and management of incidentally discovered microscopic hematuria.

Reprinted with permission from Sharp VJ, Barnes KT, Erickson BA. Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician. 2013;88(11):748.

Diagnosis and Management of Incidentally Discovered Microscopic Hematuria


Figure 1.

Algorithm for the diagnosis and management of incidentally discovered microscopic hematuria.

Reprinted with permission from Sharp VJ, Barnes KT, Erickson BA. Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician. 2013;88(11):748.

LABORATORY TESTS

To evaluate for renal impairment, serum blood urea nitrogen and creatinine levels should be obtained for all patients in whom bladder cancer is suspected.21 If metastatic disease is suspected, a complete blood count and complete metabolic panel, including alkaline phosphatase level and assessment of liver function, are appropriate.21

CYTOLOGY AND URINARY TUMOR MARKERS

Urine cytology is not recommended as part of the routine evaluation for asymptomatic microscopic hematuria21 because renal calculi and urinary tract infections can lead to false-positive results.29 It has high sensitivity (greater than 90%) for high-grade urothelial tumors and carcinoma in situ (stage Tis), although negative findings do not rule out malignancy.29 Urine cytology is an important adjunct in the evaluation of patients at high risk of urothelial tumors because of its positive predictive value in these patients.21 Urine cytology is also useful for surveillance in patients with known urothelial carcinoma.21 Routine testing for urinary tumor markers is not recommended because of lack of clinical reliability.21

CYSTOSCOPY AND TURBT

Cystoscopy should be performed in all patients with gross hematuria and in those 35 years and older with microscopic hematuria, and it can be considered for younger patients with microscopic hematuria.21 Patients with hematuria and risk factors for bladder cancer (e.g., tobacco use, irritative voiding symptoms, chemical exposures) should be evaluated with cystoscopy regardless of age.21

Patients with abnormal findings on bladder wash cytology or tissue pathology should undergo transurethral resection of the bladder tumor (TURBT). This procedure provides essential histopathologic information necessary for definitive diagnosis, staging, and grading, and allows for removal of visible tumor and sampling of surrounding muscle to assess depth.20

UPPER URINARY TRACT IMAGING

Multiphasic CT urography with and without intravenous contrast media and excretory imaging should be included in the initial workup for bladder cancer.27 It has the highest sensitivity (95%) and specificity (92%) of all upper urinary tract imaging modalities, and it can evaluate the urothelium of the upper tracts as well as detect renal masses.30 Magnetic resonance urography and ultrasonography are alternative imaging options for patients with contraindications to CT urography, such as pregnancy, contrast allergy, or renal insufficiency.21 Renal ultrasonography may be considered in addition to CT urography for patients who have suspected renal parenchymal disease.30 Renal ultrasonography is not recommended on its own for evaluation of hematuria without a known cause, because its low sensitivity (50%) may miss urothelial lesions, small renal masses, or renal calculi, and it often leads to further testing and additional costs.28 If metastatic disease is suspected, chest radiography and imaging of the abdomen and pelvis with CT or magnetic resonance imaging should be obtained.31

Screening

No major organizations recommend screening for bladder cancer in asymptomatic adults.5,17,20,27,32 In 2011, the U.S. Preventive Services Task Force concluded that there was insufficient evidence to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults,33 a statement endorsed by the American Academy of Family Physicians.34 The low positive predictive value of available screening tests and lack of high-quality evidence to suggest that early treatment of bladder cancer improves long-term outcomes preclude a recommendation in favor of screening.

Initial Treatment

Management of bladder cancer depends on the pathologic extent of disease at the time that TURBT is performed and on subsequent staging according to the tumor-node-metastasis classification system (eTable B and Figure 2 35). Non–muscle-invasive disease is most often treated with TURBT followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy in tumors with greater risk of progression or recurrence. CT or magnetic resonance imaging is often used to evaluate invasion beyond the bladder. Imaging should be done before TURBT is performed because of the possibility of a post-TURBT perivesicular reaction, which can make interpretation difficult.17 Because of the increased risk of progression and recurrence, bladder tumors that invade the muscle are typically treated by radical cystectomy with extended lymphadenectomy, preceded by cisplatin-based neoadjuvant chemotherapy.17,36 Bladder preservation is an option in certain patients, usually followed by chemotherapy and radiation.17

 Enlarge     Print

eTable B.

American Joint Committee on Cancer TNM and Clinical Staging for Bladder Cancer

Primary tumor (T)

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

Ta: Noninvasive papillary carcinoma

Tis: Carcinoma in situ (“flat tumor”)

T1: Tumor invades subepithelial connective tissue

T2: Tumor invades muscularis propria (2a superficial inner half; 2b deep outer half)

T3: Tumor invades perivesical tissue (3a microscopically; 3b macroscopically)

T4: Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall

T4a: Tumor invades prostate, uterus, vagina

T4b: Tumor invades pelvic wall, abdominal wall

Regional lymph nodes (N)*

NX: Regional lymph nodes cannot be assessed

N0: No lymph node metastasis

N1: Single regional lymph node metastasis in true pelvis

N2: Multiple regional lymph node metastasis in true pelvis

N3: Metastasis to common iliac lymph nodes

Distant metastasis (M)

M0: No distant metastasis

M1: Distant metastasis

Clinical staging

Stage 0a

Ta

N0

M0

Stage 0is

Tis

N0

M0

Stage I

T1

N0

M0

Stage II

T2a

N0

M0

T2b

N0

M0

Stage III

T3a

N0

M0

T3b

N0

M0

T4a

N0

M0

Stage IV

T4b

N0

M0

Any T

N1

M0

Any T

N2

M0

Any T

N3

M0

Any T

Any N

M1


*—Regional lymph nodes are those within the true pelvis; all others are distant lymph nodes.

Adapted with permission from Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:573–574.

eTable B.

American Joint Committee on Cancer TNM and Clinical Staging for Bladder Cancer

Primary tumor (T)

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

Ta: Noninvasive papillary carcinoma

Tis: Carcinoma in situ (“flat tumor”)

T1: Tumor invades subepithelial connective tissue

T2: Tumor invades muscularis propria (2a superficial inner half; 2b deep outer half)

T3: Tumor invades perivesical tissue (3a microscopically; 3b macroscopically)

T4: Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall

T4a: Tumor invades prostate, uterus, vagina

T4b: Tumor invades pelvic wall, abdominal wall

Regional lymph nodes (N)*

NX: Regional lymph nodes cannot be assessed

N0: No lymph node metastasis

N1: Single regional lymph node metastasis in true pelvis

N2: Multiple regional lymph node metastasis in true pelvis

N3: Metastasis to common iliac lymph nodes

Distant metastasis (M)

M0: No distant metastasis

M1: Distant metastasis

Clinical staging

Stage 0a

Ta

N0

M0

Stage 0is

Tis

N0

M0

Stage I

T1

N0

M0

Stage II

T2a

N0

M0

T2b

N0

M0

Stage III

T3a

N0

M0

T3b

N0

M0

T4a

N0

M0

Stage IV

T4b

N0

M0

Any T

N1

M0

Any T

N2

M0

Any T

N3

M0

Any T

Any N

M1


*—Regional lymph nodes are those within the true pelvis; all others are distant lymph nodes.

Adapted with permission from Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:573–574.

 Enlarge     Print

Management of Bladder Cancer

Figure 2.

Algorithm for the management of bladder cancer. (CT = computed tomography; TURBT = transurethral resection of bladder tumor.)

Reprinted with permission from Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80(7):721.

Management of Bladder Cancer


Figure 2.

Algorithm for the management of bladder cancer. (CT = computed tomography; TURBT = transurethral resection of bladder tumor.)

Reprinted with permission from Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80(7):721.

NON–MUSCLE-INVASIVE BLADDER CANCER

About 70% to 80% of bladder cancers present as non–muscle-invasive tumors. Of these, 60% to 70% are confined to the bladder mucosa (stage Ta), 20% to 30% demonstrate invasion to the subepithelial connective tissue (stage T1), and about 10% present as carcinoma in situ.20,37 The primary treatment for non–muscle-invasive bladder cancer is TURBT, usually followed by immediate instillation of BCG or intravesical chemotherapy (mitomycin C, epirubicin [Ellence], or doxorubicin [Adriamycin]). The decision to instill BCG and/or chemotherapy is based on the risk of cancer progression or recurrence.17,27 A risk calculator is available at http://www.eortc.be/tools/bladdercalculator.

For low-risk tumors (low-grade Ta), TURBT with immediate instillation of chemotherapy is recommended as complete therapy.20,27 Patients with high-risk non–muscle-invasive tumors (high-grade Ta and T1) have about a 50% chance of recurrence with muscle-invasive disease if treated with TURBT alone, and are therefore typically treated with TURBT and intravesical BCG (preferred) or mitomycin C.20,27,32 In patients with high-grade Ta or T1 tumors, 10-year recurrence-free survival after TURBT and BCG immunotherapy is about 80%.29 About one-half of patients with non–muscle-invasive carcinoma in situ will progress to muscle-invasive disease without treatment.20,32 Restaging of high-risk non–muscle-invasive tumors (high-grade Ta, T1, and Tis) with repeat TURBT two to six weeks after diagnosis and preferably before BCG instillation is recommended27,32,38 and is associated with decreased recurrence, with a number needed to treat of 3 to prevent recurrence at three months.39 Patients with high-grade T1 non–muscle-invasive tumors, especially those with high-risk features (e.g., multiple grade 3 T1 tumors with Tis, increased depth of invasion, disease progression with BCG treatment), should be considered for immediate cystectomy.17,20,27

MUSCLE-INVASIVE BLADDER CANCER

Given the aggressive nature of muscle-invasive bladder cancer, timely diagnosis and treatment are crucial.40,41 Radical cystectomy with bilateral pelvic lymphadenectomy and cisplatin-based neoadjuvant chemotherapy are strongly recommended for all patients with resectable nonmetastatic muscle-invasive bladder cancer.36 Five-year survival rates with cystectomy alone are only about 50%; neoadjuvant chemotherapy can improve survival, especially in patients at high risk of progression or recurrence (those with nodal involvement, high-grade tumors, or transmural or vascular invasion).17,20,27,29,36,4244 When used in conjunction with cystectomy, cisplatin-based neoadjuvant chemotherapy demonstrated an absolute five-year survival benefit of 5% to 8% across several trials, translating to a number needed to treat of 9.29 Segmental (partial) cystectomy and neoadjuvant cisplatin-based chemotherapy may be appropriate for select patients.27,36 Extensive lymph node dissection is associated with improvements in progression-free and overall survival.45 Compared with open surgery, a laparoscopic approach is associated with similar recurrence and survival rates, may reduce pain and the need for blood transfusion, and may speed recovery.46,47 Radical cystectomy improves survival rates compared with external beam radiotherapy and is the preferred treatment for muscle-invasive bladder cancer.48 Radiotherapy may be considered as part of a multimodal bladder-preserving approach or for palliation in patients who are not candidates for cystectomy.17,36

Chemotherapy is the preferred treatment for patients with metastatic disease or unresectable bladder cancer. The two available treatments (combination gemcitabine and cisplatin, and combination methotrexate, vinblastine, doxorubicin, and cisplatin) are associated with a median survival time of about 14 months.17

Bladder reconstruction may involve continent reservoir or ileal conduit urinary diversion, depending on tumor characteristics and patient preferences.17 However, neither approach has evidence of improvement in long-term outcomes.49

Overall survival for patients with muscle-invasive bladder cancer is 66% at five years after radical cystectomy and extensive lymph node dissection, and 50% to 60% with bladder preservation therapy.29 Radical cystectomy and reconstruction is associated with 90-day postoperative mortality rates of 3% to 9%,29,50 underscoring the emphasis on quality of life for patients older than 80 years and those with significant comorbidities.

ADJUVANT CHEMOTHERAPY

There is insufficient high-quality evidence to support routine use of adjuvant chemotherapy for patients with bladder cancer. However, chemotherapy may provide benefit in certain high-risk patients.17,51 Platinum-based combination chemotherapy may improve survival in patients with invasive bladder cancer.52 Cisplatin-based chemotherapy improves disease-free survival in those with lymph node involvement.53 Combination gemcitabine and cisplatin is associated with similar overall survival as other regimens, but may be less toxic in patients with unresectable, locally advanced, or metastatic transitional cell bladder cancer.54,55

NONUROTHELIAL BLADDER CANCER

Cystectomy, partial cystectomy, or radiation is the mainstay of treatment for most nonurothelial bladder cancers. Systemic chemotherapy is generally not used for these tumors.27

FOLLOW-UP

Follow-up is noted in Table 3 and is based on clinical staging.27,36

 Enlarge     Print

Table 3.

Follow-Up for Bladder Cancer

Tumor stageFollow-up

Low-grade Ta

Cystoscopy at three months, then at increasing intervals as appropriate

T1 or high-grade Ta

Cystoscopy and urine cytology every three to six months for two years, then at increasing intervals as appropriate

Consider imaging of the upper urinary tract every one to two years

Consider testing for urinary tumor markers for urothelial cancer

Maintenance BCG immunotherapy (preferred if used previously)

T2 or greater (muscle-invasive disease)

Urine cytology with creatinine and electrolyte levels as clinically indicated

Imaging of chest and cross-sectional imaging of abdomen and pelvis with computed tomography or magnetic resonance imaging every six to 12 months for two to three years, then annually

After bladder-sparing surgery:

Urine cytology, creatinine and electrolyte levels, and liver function tests every three to six months for two years, then as clinically indicated

Imaging as above

Cystoscopy and urine cytology with or without selected mapping biopsy every three to six months for two years, then at increasing intervals as appropriate

Consider urethral wash cytology every six to 12 months, especially in patients with carcinoma in situ within bladder or prostatic urethra

After cystectomy and continent reservoir urinary diversion, vitamin B12 level annually*


BCG = bacille Calmette-Guérin.

*—Vitamin B12 deficiency is possible after continent reservoir urinary diversion because of malabsorption that may occur from use of ileocecal segments. (Vitamin B12 is absorbed in the terminal ileum.)

Information from references 27 and 36.

Table 3.

Follow-Up for Bladder Cancer

Tumor stageFollow-up

Low-grade Ta

Cystoscopy at three months, then at increasing intervals as appropriate

T1 or high-grade Ta

Cystoscopy and urine cytology every three to six months for two years, then at increasing intervals as appropriate

Consider imaging of the upper urinary tract every one to two years

Consider testing for urinary tumor markers for urothelial cancer

Maintenance BCG immunotherapy (preferred if used previously)

T2 or greater (muscle-invasive disease)

Urine cytology with creatinine and electrolyte levels as clinically indicated

Imaging of chest and cross-sectional imaging of abdomen and pelvis with computed tomography or magnetic resonance imaging every six to 12 months for two to three years, then annually

After bladder-sparing surgery:

Urine cytology, creatinine and electrolyte levels, and liver function tests every three to six months for two years, then as clinically indicated

Imaging as above

Cystoscopy and urine cytology with or without selected mapping biopsy every three to six months for two years, then at increasing intervals as appropriate

Consider urethral wash cytology every six to 12 months, especially in patients with carcinoma in situ within bladder or prostatic urethra

After cystectomy and continent reservoir urinary diversion, vitamin B12 level annually*


BCG = bacille Calmette-Guérin.

*—Vitamin B12 deficiency is possible after continent reservoir urinary diversion because of malabsorption that may occur from use of ileocecal segments. (Vitamin B12 is absorbed in the terminal ileum.)

Information from references 27 and 36.

Treatment of Recurrent or Persistent Disease

Recurrent non–muscle-invasive bladder cancer is treated with a combination of repeat TURBT, adjuvant intravesical therapy, maintenance BCG immunotherapy, and/or cystectomy, based on tumor and grade.27 For persistent or recurrent muscle-invasive bladder cancer, cystectomy is often recommended for patients with initial bladder preservation. Intravesical BCG immunotherapy may be attempted in patients with low-risk tumors but should be followed with cystectomy if there is no response.27 Chemoradiotherapy or palliative TURBT and supportive care are recommended when recurrent or persistent disease is invasive (T2 or greater).27

Prognosis

Survival rates vary for different types of bladder cancer, with five-year rates ranging from 96% for carcinoma in situ to 5% with distant metastasis (Table 4).56

 Enlarge     Print

Table 4.

Bladder Cancer Survival by Stage

Tumor stageFive-year survival rate (%)

All

76

In situ

96

Localized

70

Regional

35

Distant

5

Unknown

46


Information from reference 56.

Table 4.

Bladder Cancer Survival by Stage

Tumor stageFive-year survival rate (%)

All

76

In situ

96

Localized

70

Regional

35

Distant

5

Unknown

46


Information from reference 56.

The Authors

show all author info

KATHARINE C. DeGEORGE, MD, MS, is an assistant professor of family medicine at the University of Virginia School of Medicine, Charlottesville....

HARRY R. HOLT, MD, is a family physician at Baltimore (Md.) Medical System. At the time this article was written, he was an assistant professor of family medicine at the University of Virginia School of Medicine.

STEPHANIE C. HODGES, MD, is a family physician at the Everett Clinic, Lake Stevens, Wash. At the time this artcile was written, she was a third-year family medicine resident at the University of Virginia School of Medicine.

Address correspondence to Katharine C. DeGeorge, MD, MS, University of Virginia, P.O. Box 800729, Charlottesville, VA 22908 (e-mail: kd6fp@mcc.virginia.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.


This article updates a previous article on this topic by Sharma, et al.35

Data Sources: A PubMed search was completed in Clinical Queries using the key terms bladder cancer, diagnosis, treatment, hematuria, urothelial mass, bladder carcinoma, carcinoma in situ, and transurethral resection of bladder tumor. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. We also searched DynaMed Plus, the Agency for Healthcare Research and Quality evidence reports, Clinical Evidence, the Cochrane database, Essential Evidence Plus, the National Comprehensive Cancer Network, and the National Guideline Clearinghouse database. Search dates: May 20, 2016, and April 28, 2017.

REFERENCES

show all references

1. American Cancer Society. Key statistics for bladder cancer. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed May 20, 2016....

2. American Cancer Society. Bladder cancer risk factors. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-risk-factors. Accessed May 20, 2016.

3. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women [published correction appears in JAMA. 2011;306(20): 2220]. JAMA. 2011;306(7):737–745.

4. Ferrucci LM, Sinha R, Ward MH, et al. Meat and components of meat and the risk of bladder cancer in the NIH-AARP Diet and Health Study. Cancer. 2010;116(18):4345–4353.

5. American Cancer Society. Can bladder cancer be found early? http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-detection. Accessed May 20, 2016.

6. Ho CH, Sung KC, Lim SW, et al. Chronic indwelling urinary catheter increase the risk of bladder cancer, even in patients without spinal cord injury. Medicine (Baltimore). 2015;94(43):e1736.

7. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12(1):97–111.

8. Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One. 2015;10(3):e0119313.

9. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346:f2360.

10. Yan L, Chen P, Chen EZ, Gu A, Jiang ZY. Risk of bladder cancer in renal transplant recipients: a meta-analysis. Br J Cancer. 2014;110(7):1871–1877.

11. Guillaume L, Guy L. Epidemiology of and risk factors for bladder cancer and for urothelial tumors (in French). Rev Prat. 2014;64(10):1372–1374, 1378–1380.

12. Janković S, Radosavljević V. Risk factors for bladder cancer. Tumori. 2007;93(1):4–12.

13. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30(9):1026–1032.

14. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13:310.

15. Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204(2):217–223.

16. Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J. 2006;99(11):1256–1263.

17. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3): iii40–iii48.

18. Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol. 2009;22(suppl 2):S60–S69.

19. Badawi AF, Mostafa MH, Probert A, O'Connor PJ. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev. 1995;4(1):45–59.

20. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.

21. Davis R, Jones JS, Barocas DA, et al.; American Urological Association. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 suppl):2473–2481.

22. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10(6): 311–322.

23. Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA. 1986;256(2):224–229.

24. Golin AL, Howard RS. Asymptomatic microscopic hematuria. J Urol. 1980;124(3):389–391.

25. American Cancer Society. Cancer facts and figures 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed May 20, 2016.

26. Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117–122.

27. Clark PE, Agarwal N, Biagioli MC, et al.; National Comprehensive Cancer Network. Bladder cancer. J Natl Compr Canc Netw. 2013;11(4):446–475.

28. Sharp VJ, Barnes KT, Erickson BA. Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician. 2013;88(11):747–754.

29. Witjes JA, Compérat E, Cowan NC, et al.; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–792.

30. American College of Radiology. ACR appropriateness criteria: hematuria. https://acsearch.acr.org/docs/69490/Narrative. Accessed May 20, 2016.

31. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:573–574.

32. Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461.

33. Moyer VA; U.S. Preventive Services Task Force. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2011;155(6):408.] Ann Intern Med. 2011;155(4):246–251.

34. American Academy of Family Physicians. Clinical preventive service recommendation: bladder cancer. https://www.aafp.org/patient-care/clinical-recommendations/all/bladder-cancer.html. Accessed May 20, 2016.

35. Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80(7):717–723.

36. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. Published online ahead of print April 26, 2017. http://www.sciencedirect.com/science/article/pii/S0022534717578362. Accessed June 6, 2017.

37. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64.

38. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029.

39. Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. 2014;191(2):341–345.

40. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22):5235–5242.

41. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis. Cancer. 2009;115(5):988–996.

42. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350–357.

43. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published ocrrection appears in N Engl J Med. 2003; 349(19):1880]. N Engl J Med. 2003;349(9):859–866.

44. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16): 2171–2177.

45. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296–1300.

46. Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015;67(6):1042–1050.

47. Yuh B, Wilson T, Bochner B, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur Urol. 2015;67(3):402–422.

48. Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev. 2002;(1): CD002079.

49. Cody JD, Nabi G, Dublin N, et al. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev. 2012;(2): CD003306.

50. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185(1):72–78.

51. Ruggeri EM, Fabbri MA, Nelli F. Should we use adjuvant chemotherapy for muscle-invasive bladder cancer after radical cystectomy? J Clin Oncol. 2016;34(26):3223.

52. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005;(2):CD005246.

53. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.

54. Shelley M, Cleves A, Wilt TJ, Mason M. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev. 2011;(4):CD008976.

55. Shelley MD, Cleves A, Wilt TJ, Mason MD. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU Int. 2011; 108(2):168–179.

56. National Cancer Institute. Cancer stat facts: bladder cancer. http://seer.cancer.gov/statfacts/html/urinb.html. Accessed May 27, 2016.

 

 

Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Nov 15, 2018

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article